StockNews.com began coverage on shares of Veradigm (NASDAQ:MDRX – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the software maker’s stock.
Separately, TD Cowen decreased their price objective on Veradigm from $26.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $12.00.
Check Out Our Latest Stock Report on Veradigm
Veradigm Stock Performance
Institutional Trading of Veradigm
A number of large investors have recently added to or reduced their stakes in MDRX. Innealta Capital LLC bought a new stake in shares of Veradigm in the 2nd quarter valued at about $38,000. TFO Wealth Partners LLC increased its position in Veradigm by 105,280.0% during the fourth quarter. TFO Wealth Partners LLC now owns 5,269 shares of the software maker’s stock worth $52,000 after buying an additional 5,264 shares during the last quarter. Gladius Capital Management LP raised its stake in Veradigm by 135.0% in the fourth quarter. Gladius Capital Management LP now owns 6,245 shares of the software maker’s stock valued at $66,000 after buying an additional 3,587 shares during the period. Meadow Creek Wealth Advisors LLC acquired a new stake in shares of Veradigm in the first quarter valued at approximately $83,000. Finally, Forest Hill Capital LLC bought a new position in shares of Veradigm during the 4th quarter worth approximately $210,000.
Veradigm Company Profile
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Read More
- Five stocks we like better than Veradigm
- 3 Stocks to Consider Buying in October
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- 5 Top Rated Dividend Stocks to Consider
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.